Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.680
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2013
Authors
Publisher
Elsevier BV